natgillin/translations-raw huggingface dataset:
In the analysis of responder rates (the non-completer equals failure analysis [NC = F]), patients who terminated the study early for any reason, or who had a missing HIV-RNA measurement that was either preceded or followed by a measurement above the limit of assay quantification were considered to have HIV-RNA above 50 or above 400 copies/ml at the missing time points.
U analizi stopa bolesnika s odgovorom (ispitanici koji nisu završili liječenje nisu analizirani; engl. the non-completer equals failure analysis, [NC=F]), za one bolesnike koji su iz bilo kojeg razloga ranije prekinuli ispitivanje, ili one koji su propustili jedno mjerenje HIV-RNK kojemu je prethodilo ili je nakon njega uslijedilo mjerenje s rezultatima iznad granice određivanja laboratorijskog testa, pretpostavljeno je da imaju HIV-RNK iznad 50 ili iznad 400 kopija/ml u vrijeme propuštenog mjerenja.
Lipid disorders should be managed as clinically appropriate
Poremećaje lipida potrebno je prikladno klinički liječiti.
The pattern of amino acid substitutions in RT associated with resistance to efavirenz was independent of the other antiviral medicines used in combination with efavirenz.
Obrazac aminokiselinskih zamjena u reverznoj transkriptazi udruženih s rezistencijom na efavirenz bio je neovisan o drugim antivirusnim lijekovima u kombinaciji s efavirenzom.
Carcinogenicity studies in male mice, male and female rats were negative.
Istraživanja kancerogenosti kod mužjaka miševa te kod mužjaka i ženki štakora bila su negativna.
- abnormal dreams, difficulty concentrating, dizziness, headache, difficulty sleeping, drowsiness,
- neuobičajeni snovi, poteškoće s koncentracijom, omaglica, glavobolja, poteškoće sa spavanjem,
Efavirenz may be an inducer of CYP2C19 and CYP2C9; however inhibition has also been observed in vitro and the net effect of co-administration with substrates of these enzymes is not clear (see section 5.2).
Efavirenz može biti induktor CYP2C19 i CYP2C9; međutim in vitro je zabilježena i inhibicija, tako da neto učinak istodobne primjene sa supstratima tih enzima nije razjašnjen (vidjeti dio 5.2).
Relevant examples are cytomegalovirus retinitis, generalised and/or focal mycobacterial infections, and pneumonia caused by Pneumocystis jiroveci (formerly known as Pneumocystis carinii).
Odgovarajući primjeri su citomegalovirusni retinitis, opće i/ili lokalizirane infekcije mikobakterijama i upala pluća izazvana Pneumocystis jiroveci (prije poznata kao
Efavirenz Teva, which contains the active substance efavirenz, belongs to a class of antiretroviral medicines called non-nucleoside reverse transcriptase inhibitors (NNRTIs).
Efavirenz Teva, koji sadrži djelatnu tvar efavirenz, pripada skupini antiretrovirusnih lijekova koji se nazivaju nenukleozidni inhibitori reverzne transkriptaze (NNRTI).
Responder rates were highest in patients who switched NRTIs.
Stope bolesnika s odgovorom bile su najveće među bolesnicima koji su promijenili NRTI.
If you are affected your doctor may suggest that you take Efavirenz Teva at bedtime and on an empty stomach.
Ako se u Vas pojave opisani simptomi, liječnik Vam može predložiti da Efavirenz Teva uzimate prije spavanja i na prazan želudac.
Study number/ Treatment regimensb n % (95% C.I.c) % (95% C.I.c) cells/mm3
Broj ispitivanja/ Terapijski protokoli b n % (95% C.I.c) % (95% C.I.c) stanica/mm3 (S.E.M.d)
Patients should be advised to seek medical advice if they experience joint aches and pain, joint stiffness or difficulty in movement.
Bolesnike treba uputiti da potraže liječničku pomoć osjete li stalnu tupu bol i povremenu bol ili ukočenost zglobova ili imaju poteškoća u kretanju.
In clinical controlled trials, frequently reported adverse reactions included, but were not limited to dizziness, insomnia, somnolence, impaired concentration and abnormal dreaming.
U kontroliranim kliničkim ispitivanjima često su zabilježene sljedeće (ali ne samo ove) nuspojave: omaglica, nesanica, somnolencija, smanjena koncentracija i neuobičajeni snovi.
K103N was the most frequently observed RT substitution in viral isolates from patients who experienced a significant rebound in viral load during clinical studies of efavirenz in combination with indinavir or zidovudine + lamivudine.
K103N je bila najčešće zabilježena zamjena RT u virusnim izolatima u bolesnika koji su imali značajan povrat (rebound) virusnog opterećenja tijekom kliničkih ispitivanja primjene efavirenza u kombinaciji s indinavirom ili zidovudinom + lamivudinom.
These problems tend to occur more often in those who have a history of mental illness.
Te nuspojave češće se javljaju u bolesnika koji su bolovali od neke psihičke bolesti.
If you notice any symptoms of infection, please tell your doctor immediately.
Primijetite li bilo kakve simptome infekcije, odmah obavijestite svog liječnika.
The steady-state AUC, Cmax and Cmin of the active carbamazepine epoxide metabolite remained unchanged.
Cmax i Cmin aktivnog metabolita karbamazepin epoksida ostale su nepromijenjene.
Implant: Etonogestrel/efavirenz Decreased exposure of etonogestrel may be expected (CYP3A4 induction).
Implantat: Etonogestrel/efavirenz Može se očekivati smanjena izloženost etonogestrelu (indukcija CYP3A4).
In clinical studies, 26% of patients treated with 600 mg of efavirenz experienced skin rash compared with 17% of patients treated in control groups.
U kliničkim je ispitivanjima 26% bolesnika liječenih efavirenzom od 600 mg imalo kožni osip, u odnosu na 17% onih u kontrolnim skupinama.
Each film-coated tablet contains 9.98 mg lactose (as monohydrate).
Jedna filmom obložena tableta sadrži 9,98 mg laktoze (u obliku hidrata).
Pregnancies have occurred in women taking Efavirenz Teva while using a contraceptive implant, although it has not been established that the Efavirenz Teva therapy caused the contraceptive to fail.
Trudnoća je nastupila u žena koje su uzimale Efavirenz Teva i koristile kontracepcijski implantat, premda nije potvrđeno da je liječenje lijekom Efavirenz Teva spriječilo djelovanje kontraceptiva.
Concomitant administration of sofosbuvir/velpatasvir with efavirenz resulted in a reduction (approximately 50%) in the systemic exposure of velpatasvir.
Istodobna primjena sofosbuvira/velpatasvira s efavirenzom uzrokovala je smanjenje (približno 50%) sistemske izloženosti
Exposures of raltegravir (a UGT1A1 substrate) are reduced in the presence of efavirenz (see section 4.5, table 1).
Izloženost raltegraviru (supstrat UGT1A1) smanjena je u prisustvu efavirenza (vidjeti dio 4.5, Tablicu 1).
†These adverse reactions were identified through post-marketing surveillance; however, the frequencies were determined using data from 16 clinical trials (n=3,969).
† Ove nuspojave zabilježene su tijekom praćenja nakon stavljanja lijeka u promet; no, učestalost je određena na temelju podataka iz 16 kliničkih ispitivanja (n=3969).
This medicine contains less than 1 mmol sodium (23 mg) per tablet that is to say essentially ‘sodiumfree'.
Ovaj lijek sadrži manje od 1 mmol (23 mg) natrija po tableti, tj. zanemarive količine natrija.
Talk to your doctor before taking Efavirenz Teva
Obratite se svom liječniku prije nego što uzmete Efavirenz Teva.
The potential for cross-resistance between efavirenz and NRTIs is low because of the different binding sites on the target and mechanism of action.
Potencijal križne rezistencije između efavirenza i NRTI-ja je također je nizak zbog različitih veznih mjesta i mehanizama djelovanja.
Efavirenz plasma exposure may be increased in patients with the homozygous G516T genetic variant of the CYP2B6 isoenzyme.
Koncentracija efavirenza u plazmi može biti povišena u bolesnika s homozigotnom G516T genskom inačicom izoenzima CYP2B6.
In patients treated with other medicinal products associated with liver toxicity, monitoring of liver enzymes is also recommended.
U bolesnika koji se liječe drugim lijekovima s hepatotoksičnim učinkom, također se preporučuje praćenje jetrenih enzima.
Efavirenz Teva may interact with other medicines, including herbal preparations such as Ginkgo biloba extracts.
Moguće su interakcije Efavirenza Teva s nekim drugim lijekovima, uključujući biljne pripravke kao što su ekstrakti Ginkga bilobe.
Patients who are receiving concomitant anticonvulsant medicinal products primarily metabolised by the liver, such as phenytoin, carbamazepine and phenobarbital, may require periodic monitoring of plasma levels.
U bolesnika koji istodobno primaju antikonvulzive koji se primarno metabolizira u jetri kao što su fenitoin, karbamazepin i fenobarbital može biti potrebno povremeno provjeravati koncentracije u plazmi.
Thirteen isolates previously characterised as efavirenz-resistant were also resistant to nevirapine and delavirdine.
Trinaest izolata, za koje je prethodno ustanovljeno da su rezistentni na efavirenz, bilo je rezistentno i na nevirapin i delavirdin.
If efavirenz and telaprevir are coadministered, telaprevir 1,125 mg every 8 hours should be used.
U slučaju istovremene primjene efavirenza i telaprevira, telaprevir 1,125 mg potrebno je primjenjivati svakih 8 sati.
The recommended dose of efavirenz in combination with nucleoside analogue reverse transcriptase inhibitors (NRTIs) with or without a PI (see section 4.5) is 600 mg orally, once daily.
Preporučena doza efavirenza u kombinaciji s nuklezoidnim analozima inhibitora reverzne transkriptaze (engl. nucleoside analogue reverse transcriptase inhibitors, NRTIs) s inhibitorom proteaze ili bez njega (vidjeti dio 4.5), je 600 mg peroralno, jedanput na dan.
A few of the postmarketing reports of hepatic failure occurred in patients with no pre-existing hepatic disease or other identifiable risk factors (see section 4.8).
Nakon stavljanja lijeka u promet prijavljeno je nekoliko slučajeva zatajenja jetre u bolesnika koji nisu imali postojeću bolest jetre niti druge prepoznatljive čimbenike rizika (vidjeti dio 4.8).
30 film-coated tablets 30 x 1 film-coated-tablets 90 x 1 film-coated tablets 90 film-coated tablets
30 filmom obloženih tableta 30 x 1 filmom obložena tableta 90 x 1 filmom obloženih tableta 90 filmom obloženih tableta
Although in vitro data suggest that efavirenz inhibits CYP2C9 and CYP2C19, there have been contradictory reports of both increased and decreased exposures to substrates of these enzymes when coadministered with efavirenz in vivo.
Iako in vitro podaci upućuju da efavirenz inhibira CYP2C9 i CYP2C19, postoje kontradiktorna izvješća i o povećanoj i o smanjenoj izloženosti supstratima tih enzima tijekom njihove istodobne primjene s efavirenzom in vivo.
- Medicines used to lower blood fats (also called statins): atorvastatin, pravastatin, simvastatin.
- Lijekove za snižavanje masnoća u krvi (statine): atorvastatin, pravastatin, simvastatin.
There is no experience in patients with severe renal failure and close safety monitoring is recommended in this population.
Budući da nema iskustva kod primjene u bolesnika s teškim zatajenjem bubrega, u toj se skupini preporuča strogi sigurnosni nadzor.
In these studies the dose of efavirenz was 600 mg once daily; the dose of indinavir was 1,000 mg every 8 hours when used with efavirenz and 800 mg every 8 hours when used without efavirenz.
U tim je studijama efavirenz primjenjivan u dozi od 600 mg jedanput na dan; doza indinavira bila je 1000 mg svakih 8 sati kad se primjenjivao u kombinaciji s efavirenzom, odnosno 800 mg svakih 8 sati kad se primjenjivao bez efavirenza.
Sufficient data on the tolerability of efavirenz with low-dose ritonavir (100 mg, once or twice daily) are not available.
Nema dovoljno podataka o podnošljivosti efavirenza s niskom dozom ritonavira (100 mg jedanput ili dvaput na dan).
Efavirenz has also been shown to induce UGT1A1.
Efavirenz također inducira UGT1A1.
- Sertraline (a medicine used to treat depression): your doctor may need to change your dose of sertraline.
- Sertralin (lijek za liječenje depresije): liječnik će Vam možda trebati promijeniti dozu sertralina.
In a 3-month drug interaction study, no significant differences in MPA pharmacokinetic parameters were found between subjects receiving efavirenz-containing antiretroviral therapy and subjects receiving no antiretroviral therapy.
U tromjesečnom ispitivanju interakcija lijekova nisu ustanovljene značajne razlike u farmakokinetičkim parametrima MPA između ispitanika koji su primali antiretrovirusnu terapiju koja je sadržavala efavirenz i ispitanika koji nisu primali antiretrovirusnu terapiju.
Taking these medicines with Efavirenz Teva could create the potential for serious and/or life-threatening side effects or stop Efavirenz Teva from working properly.
Uzimanje ovih lijekova s Efavirenzom Teva može dovesti do razvoja ozbiljnih i/ili po život opasnih nuspojava ili spriječiti ispravno djelovanje Efavirenza Teva.
Although cross-resistance of efavirenz with PIs has not been documented, there are at present insufficient data on the efficacy of subsequent use of PI-based combination therapy after failure of regimens containing efavirenz.
Iako nije dokazana ukrižena rezistencija efavirenza s inhibitorima proteaze, zasad nema dovoljno podataka o djelotvornosti naknadne primjene kombinirane terapije inhibitorima proteaze nakon neuspjeha terapije koja je sadržavala efavirenz.
Reported rates of recurrent rash following a switch from nevirapine to efavirenz therapy, primarily based on retrospective cohort data from published literature, range from 13 to 18%, comparable to the rate observed in patients treated with efavirenz in clinical studies (see section 4.4).
Opažene stope rekurentnog osipa nakon prelaska s liječenja nevirapinom na liječenje efavirenzom, na temelju podataka iz retrospektivnih kohortnih ispitivanja iz objavljene literature, kreću se od 13 do 18%, što je usporedivo sa stopama opaženim u bolesnika liječenih efavirenzom u kliničkim ispitivanjima (vidjeti dio 4.4).).
A multiple-dose study showed no significant effect on efavirenz pharmacokinetics in patients with mild hepatic impairment (Child-Pugh Class A) compared with controls.
Ispitivanje s višekratnim dozama nije pokazalo značajan učinak na farmakokinetiku efavirenza u bolesnika s blagim oštećenjem jetre (Child-Pugh stadij A) u odnosu na kontrolnu skupinu.
Two of three delavirdine-resistant clinical isolates examined were cross-resistant to efavirenz and contained the K103N substitution.
Dva od tri ispitana klinička izolata rezistentna na delavirdin bila su križno rezistentna na efavirenz i imala su zamjenu K103N.
Phenytoin, phenobarbital, and other anticonvulsants that are substrates of CYP450 isoenzymes
Fenitoin, fenobarbital i drugi antikonvulzivi koji su supstrati izoenzima CYP450
White opaque PVC/PVdC-aluminium or aluminium-aluminium blisters in a carton containing 30 or 90 film-coated tablets.
Bijeli, neprozirni, PVC/PVdC-aluminijski ili aluminij-aluminijski blisteri u kutiji sa 30 ili 90 filmom obloženih tableta.
Efavirenz has been shown to induce CYP3A4 and CYP2B6, resulting in the induction of its own metabolism which may be clinically relevant in some patients.
Pokazalo se da efavirenz inducira CYP3A4 i CYP2B6, što dovodi do indukcije njegovog vlastitog metabolizma i može biti klinički značajno u nekih bolesnika.
Recommendation concerning co-administration with efavirenz once daily)
Preporuke vezano za istodobnu primjenu s efavirenzom jedanput na dan)
There is a potential for reduction or increase in the plasma concentrations of phenytoin, phenobarbital and other anticonvulsants that are substrates of CYP450 isoenzymes when co-administered with efavirenz.
Postoji mogućnost sniženja ili povišenja plazmatske koncentracije fenitoina, fenobarbitala i drugih antikonvulziva koji su supstrati izoenzima CYP450 kad se primjenjuju istodobno s efavirenzom.
If you forget to take Efavirenz Teva
Ako ste zaboravili uzeti Efavirenz Teva
Two controlled studies (006 and ACTG 364) of approximately one-year duration with efavirenz in combination with NRTIs and/or PIs, have demonstrated reduction of viral load below the limit of quantification of the assay and increased CD4 lymphocytes in antiretroviral therapy-naïve and NRTI-experienced HIV infected patients.
Dvije kontrolirane studije (006 i ACTG 364) u trajanju od oko godinu dana u kojima je efavirenz primjenjivan u kombinaciji s NRTI-jima i/ili inhibitorima proteaze pokazale su smanjenje virusnoga opterećenja ispod granice određivanja laboratorijskog testa, te porast CD4 limfocita u bolesnika zaraženih HIV virusom bez prethodnog antiretrovirusnog liječenja kao i u onih koji su primali NRTI
Patients should be monitored carefully for dose-related adverse reactions, especially nervous system symptoms.
Takve bolesnike treba pomno nadzirati zbog pojave nuspojava ovisnih o dozi, posebno simptoma sa strane živčanog sustava.
Table 3: Efficacy results for studies ACTG 364 and 020 Responder rates (NC = Fa) Plasma HIV-RNA
Tablica 3: Rezultati djelotvornosti iz ispitivanja ACTG 364 i 020 Stope bolesnika s odgovorom (NC = Fa) HIV-RNK u plazmi
Efavirenz must be given in combination with other antiretroviral medicines (see section 4.5).
Doziranje Efavirenz se mora primjenjivati u kombinaciji s drugim antiretrovirusnim lijekovima (vidjeti dio 4.5).
IMMUNOSUPPRESSANTS Immunosuppressants metabolized by CYP3A4 (e.g. cyclosporine, tacrolimus, sirolimus)/efavirenz
Imunosupresivi koji se metaboliziraju putem CYP3A4 (npr. ciklosporin, takrolimus, sirolimus)/efavirenz
PARTICULARS TO APPEAR ON THE OUTER PACKAGING CARTON FOR BLISTER PACK CONTAINING OF <30><30x1><90><90 x 1> EFAVIRENZ TEVA 600 mg FILM-COATED TABLETS
PODACI KOJI SE MORAJU NALAZITI NA VANJSKOM PAKIRANJU KUTIJA ZA PAKIRANJE S BLISTEROM SADRŽI <30><30x1><90><90 x 1> EFAVIRENZ TEVA 600 mg FILMOM OBLOŽENIH
Because of the extensive cytochrome P450-mediated metabolism of efavirenz and limited clinical experience in patients with chronic liver disease, caution must be exercised in administering efavirenz to patients with mild hepatic impairment.
Zbog značajnog metaboliziranja efavirenza posredstvom citokroma P-450 i zbog ograničenih kliničkih iskustava u bolesnika s kroničnom bolesti jetre, treba biti oprezan u primjeni efavirenza u bolesnika s blagom do umjerenom bolesti jetre.
The film-coating agent contains hypromellose, lactose monohydrate, titanium dioxide, macrogol/PEG 3350, triacetin and iron oxide yellow.
Sastojak film ovojnice sadrži hipromelozu, laktozu hidrat, titanijev dioksid, makrogol/PEG 3350, triacetin i žuti željezov oksid.
Time to peak plasma concentrations (3-5 hours) did not change following multiple dosing and steady-state plasma concentrations were reached in 67 days.
Vrijeme potrebno za postizanje vršne koncentracije (3-5 sati), nije se mijenjalo kod višekratnog doziranja, a koncentracije u stanju dinamičke ravnoteže postizale su se nakon 6-7 dana.
In in vitro studies efavirenz did not inhibit CYP2E1 and inhibited CYP2D6 and CYP1A2 only at concentrations well above those achieved clinically.
U istraživanjima in vitro efavirenz nije inhibirao CYP2E1, a CYP2D6 i CYP1A2 je inhibirao samo pri koncentracijama koje su bile znatno više od onih u kliničkoj primjeni.
Experience with efavirenz in patients who discontinued other antiretroviral agents of the NNRTI class is limited (see section 4.8).
Iskustvo s primjenom efavirenza u bolesnika koji su prekinuli terapiju drugim antiretrovirusnim lijekovima iz klase NNRTI-a je ograničeno (vidjeti dio 4.8).
The effect of efavirenz on male and female fertility in rats has only been evaluated at doses that achieved systemic drug exposures equivalent to or below those achieved in humans given recommended doses of efavirenz.
Učinak efavirenza na plodnost mužjaka i ženki štakora ispitivan je samo pri dozama kojima se postiže sistemska izloženost lijeku jednaka ili manja sistemskoj izloženosti u ljudi koji su primali preporučene doze efavirenza.
The mechanism of tumour formation and the potential relevance for humans are not known.
Nije poznat mehanizam nastajanja tumora, kao ni mogući značaj u ljudi.
2-hydroxy atorvastatin:
2-hidroksi atorvastatin:
The long-term safety profile of efavirenz-containing regimens was evaluated in a controlled trial (006) in which patients received efavirenz + zidovudine + lamivudine (n = 412, median duration 180 weeks), efavirenz + indinavir (n = 415, median duration 102 weeks), or indinavir + zidovudine + lamivudine (n = 401, median duration 76 weeks).
Dugoročan sigurnosni profil protokola s efavirenzom ispitan je u kontroliranom ispitivanju (006) u kojemu su bolesnici primali efavirenz + zidovudin + lamivudin (n=412, medijan trajanja 180 tjedana), efavirenz + indinavir (n=415, medijan trajanja 102 tjedna) ili indinavir + zidovudin + lamivudin (n=401, medijan trajanja 76 tjedana).
A few of the postmarketing reports of hepatic failure, including cases in patients with no pre-existing hepatic disease or other identifiable risk factors, were characterized by a fulminant course, progressing in some cases to transplantation or death.
U nekoliko prijavljenih slučajeva, nakon stavljanja lijeka u promet, uključujući i one bez prethodne bolesti jetre ili drugih prepoznatljivih čimbenika rizika, opisan je fulminantni tijek, koji je u nekim slučajevima napredovao do transplantacije ili smrti.
Cmin: ↓ 12% (↓ 24% to ↑ 1%)
Cmin: ↓ 12% (↓ 24% do ↑ 1%)
- Medicines used to treat fungal infections (antifungals):
- Lijekove za liječenje gljivičnih infekcija (antimikotike):
Do not take Efavirenz Teva).
Ne uzimajte Efavirenz Teva).
‡These adverse reactions were identified through post-marketing surveillance but not reported as drug-related events for efavirenz-treated patients in 16 clinical trials.
‡ Ove nuspojave zabilježene su tijekom praćenja nakon stavljanja lijeka u promet, ali nisu prijavljene kao nuspojave povezane s lijekom u bolesnika liječenih efavirenzom u 16 kliničkih ispitivanja.
Study 020 showed similar activity in NRTI-experienced patients over 24 weeks.
Studija 020 pokazala je sličan učinak tijekom 24-tjedne primjene u bolesnika koji su već primali
In a study of uninfected volunteers, a representative nervous system symptom had a median time to onset of 1 hour post-dose and a median duration of 3 hours.
U ispitivanju nezaraženih dobrovoljaca tipični simptomi živčanog sustava javljali su se s medijanom vremena pojave od 1 sat nakon uzimanja lijeka, te s medijanom trajanja od
Non-sustained convulsions were observed in some monkeys receiving efavirenz for ≥ 1 year, at doses yielding plasma AUC values 4- to 13-fold greater than those in humans given the recommended dose (see sections 4.4 and 4.8).
Nepostojane konvulzije zapažene su kod nekih majmuna koji su efavirenz primali ≥1 godine u dozama kojima su postignute vrijednosti AUC 4 do 13 puta veće od onih u ljudi koji su primali preporučenu dozu lijeka (vidjeti dijelove 4.4 i 4.8).
In HIV infected patients with severe immune deficiency at the time of initiation of combination antiretroviral therapy (CART), an inflammatory reaction to asymptomatic or residual opportunistic infections may arise.
U pacijenata inficiranih HIV-om s teškom imunodeficijencijom u vrijeme početka kombinirane antiretrovirusne terapije (CART) može nastati upalna reakcija na asimptomatske ili rezidualne oportunističke infekcije.
The potential for cross-resistance between efavirenz and PIs is low because of the different enzyme targets involved.
Potencijal za križnu rezistenciju između efavirenza i inhibitora proteaze je nizak, zbog vezanja na različite ciljne enzime.
(CYP3A4 induction) Co-administration of efavirenz with atorvastatin, pravastatin, or simvastatin did not affect efavirenz AUC or Cmax values.
(indukcija CYP3A4) Istodobna primjena efavirenza s atorvastatinom, pravastatinom ili simvastatinom nije utjecala na vrijednosti AUC ni Cmax efavirenza
The dose of lopinavir/ritonavir tablets should be increased to 500/125 mg twice daily when co-administered with efavirenz 600 mg once daily.
Dozu lopinavir/ritonavir tableta treba povisiti na 500/125 mg dvaput na dan kada se primjenjuju istodobno s efavirenzom u dozi od 600 mg jedanput na dan.
In clinical studies 2% of patients treated with efavirenz discontinued therapy due to such symptoms.
2% bolesnika liječenih efavirenzom prekinulo terapiju zbog ovih simptoma.